SELLAS Life Sciences SLS
NASDAQ SLS
$12.31 +0.80 (+6.95%)
At close: Sep 30, 2026 · 4:00 PM EDT

SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021)

Updated

SELLAS Life Sciences (SLS) reported Current Deferred Revenue of $900,000 for Q1 2021, down 83.9% from the prior quarter.

Analysis

SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021) Analysis & Trends

At the end of FY2020, SELLAS Life Sciences posted Current Deferred Revenue of $5.6 million.

  • The Q1 2021 figure ranks as the lowest quarterly Current Deferred Revenue since Q4 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 SELLAS Life Sciences 2.49 Bn 2.49 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 900,000.00
Dec 31, 2020 5.60 Mn
Dec 31, 2011 816,000.00
Sep 30, 2011 877,000.00
Jun 30, 2011 578,000.00
API Access

SELLAS Life Sciences Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=SLS&period=max&api_key=YOUR_API_KEY